Yazan Abou-Ismail,
MD
Languages Spoken: Arabic, English
Yazan Abou-Ismail, MD (Mouhamed Yazan Abou-Ismail) is an Assistant Professor of Medicine at the Division of Hematology and Hematologic Malignancies. He specializes in treating non-malignant hematologic disorders, with special clinical interest in disorders of hemostasis and thrombosis, in which he has authored many peer-reviewed publications. Dr. Abou-Ismail's clinical and research interests include thrombotic microangiopathies such thrombotic thrombocytopenic purpura, immune-mediated disorders of coagulation, myeloproliferative neoplasms, as well as transgender hematology. Dr. Abou-Ismail earned his medical degree from Weill Cornell Medicine in Doha, Qatar in 2014, and then completed three years of Internal Medicine residency training at Rochester General Hospital in Rochester, New York. Afterwards, he completed three years of Hematology and Oncology fellowship training at Case Western Reserve University, in Cleveland, OH, where he was the recipient of the 2018 Harris Foundation award for hematology fellows.
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine American Board of Internal Medicine (Sub: Hematology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.7/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
March 14, 2022
HUNTSMAN CANCER CENTER
Very good
UofU Patient
March 09, 2022
HUNTSMAN CANCER CENTER
I'm def never going to see a different doc there unless I have to. He's been amazing!
UofU Patient
March 07, 2022
HUNTSMAN CANCER CENTER
Good bedside manner
UofU Patient
January 31, 2022
HUNTSMAN CANCER CENTER
Dr. Abou-Ismail is an excellent listener and explainer.
UofU Patient
January 31, 2022
HUNTSMAN CANCER CENTER
Extremely pleased with entire process
UofU Patient
January 17, 2022
HUNTSMAN CANCER CENTER
Dr Abou-Ismail is a lovely person, knowledgable and friendly. MA Michael also great.
UofU Patient
December 20, 2021
HUNTSMAN CANCER CENTER
Wants to further evaluate possible diagnosis thru more lab work
UofU Patient
November 08, 2021
HUNTSMAN CANCER CENTER
Very good
UofU Patient
October 11, 2021
HUNTSMAN CANCER CENTER
Overall, I had a great experience with this Dr.
UofU Patient
September 23, 2021
HUNTSMAN CANCER CENTER
What a great doctor! This was one of the best doctor consultations I can remember. He arrived promptly, was professional and empathetic, courteous and respectful throughout the exam. He walked me through everything - tests ordered, medical history, any questions and demystified the science. His follow up was quick, thorough and gave clear answers and direction. I wish there were more doctors like Dr. Abou-Ismail.
UofU Patient
August 25, 2021
HUNTSMAN CANCER CENTER
Could have used a little more info on the medical name for the infusion and why he chose that drug.over others on the market
UofU Patient
August 24, 2021
HUNTSMAN CANCER CENTER
I have always felt like the doctor truly cared about me. Felt like he took his time and explained everything and gave options to proceed. Very kind and caring!
UofU Patient
May 17, 2021
HUNTSMAN CANCER CENTER
one of the best experiences I have EVER had with a doctor at the U of U or at any time. He is a gem and should be head of a training experience ASAP!
UofU Patient
February 03, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
January 11, 2021
HUNTSMAN CANCER CENTER
He was extremely kind and concerned about my health. He will follow up with me in two weeks from the day I was in there. I read his summary online and it was very helpful.
Yazan Abou-Ismail, MD (Mouhamed Yazan Abou-Ismail) is an Assistant Professor of Medicine at the Division of Hematology and Hematologic Malignancies. He specializes in treating non-malignant hematologic disorders, with special clinical interest in disorders of hemostasis and thrombosis, in which he has authored many peer-reviewed publications. Dr. Abou-Ismail's clinical and research interests include thrombotic microangiopathies such thrombotic thrombocytopenic purpura, immune-mediated disorders of coagulation, myeloproliferative neoplasms, as well as transgender hematology. Dr. Abou-Ismail earned his medical degree from Weill Cornell Medicine in Doha, Qatar in 2014, and then completed three years of Internal Medicine residency training at Rochester General Hospital in Rochester, New York. Afterwards, he completed three years of Hematology and Oncology fellowship training at Case Western Reserve University, in Cleveland, OH, where he was the recipient of the 2018 Harris Foundation award for hematology fellows.
Academic Locations
Huntsman Cancer Hospital
801-585-3229
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Hematology/BMT |
| Board Certification | American Board of Internal Medicine American Board of Internal Medicine (Sub: Hematology) |
Education History
| Fellowship | Case Western Reserve University Hematology & Oncology Fellow, 2020 |
| Residency | Rochester General Hospital Internal Medicine Resident, 2017 |
| Professional Medical | Weill Cornell Medical College in Qatar Medicine M.D., 2014 |
| Doctoral Training | Weill Cornell Medical College in Qatar Premedical Program , 2010 |
Selected Publications - Journal Articles
Journal Article
- Kanack A, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen M, Splinter N, Christ M, Naumann M, Moser KA, Smock KJ, Grazioli A, Wen R, Wang D, Murray DL, Padmanabhan A (2022). Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT. Blood.
- Abou-Ismail MY, Kanack A, Splinter N, Smock KJ, Moser K, Padmanabhan A (2022). Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT. Blood Adv.
- Abou-Ismail MY, Fraser R, Allbee-Johnson M, Metheny L 3rd, Ravi G, Ahn KW, Bhatt NS, Lazarus HM, de Lima M, El Jurdy N, Hematti P, Beitinjaneh AM, Nishihori T, Badawy SM, Sharma A, Pasquini MC, Savani BN, Sorror ML, Stadtmauer EA, Chhabra S (2022). Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation? Br J Haematol, 197, 326-338.
- Kanack AJ, Singh B, George G, Gundabolu K, Koepsell SA, Abou-Ismail MY, Moser KA, Smock KJ, Green D, Major A, Chan CW, Wool GD, Reding M, Ashrani AA, Bayas A, Grill DE, Padmanabhan A (2022). Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol, 97, 519-526.
- Abou-Ismail MY, Connell NT (2021). How to manage bleeding disorders in aging patients needing surgery. Hematology Am Soc Hematol Educ Program, 2021(1), 529-535.
- Abou-Ismail MY, Prchal JT, Deininger MW, Parker CJ, Lim MY (2021). Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. Blood Coagul Fibrinolysis, 32, 578-583.
- Abou-Ismail MY, Ravi G, Fu P, Cao S, Vuyyala S, Caimi P, Kolk M, Ferrari N, Boughan K, Cooper B, Gallogly M, Otegbeye F, Tomlinson B, de Lima M, Metheny L (2020). History of drug use in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant, 56(3), 581-585.
- Abou-Ismail MY, Rodgers GM, Bray PF, Lim MY (2021). Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. Res Pract Thromb Haemost, 5(2), 356-365.
- Abou-Ismail MY, Arafah Y, Fu P, Cao S, Schmaier AH, Nayak L (2020). Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab. Front Med (Lausanne), 7, 588526.
- Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L (2020). The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res, 194, 101-115.
- Abou-Ismail MY, Citla Sridhar D, Nayak L (2020). Estrogen and thrombosis: A bench to bedside review. Thromb Res, 192, 40-51.
- Abou-Ismail MY, Vuyyala S, Prunty J, Schmaier AH, Nayak L (2020). Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors. Haemophilia, 26(4), 601-606.
- Citla Sridhar D, Abou-Ismail MY, Ahuja SP (2020). Central venous catheter-related thrombosis in children and adults. Thromb Res, 187, 103-112.
- Abou-Ismail MY, Ogunbayo GO, Secic M, Kouides PA (2017). Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: A two decade study. Am J Hematol, 93(2), 232-237.
Review
Letter
- Lim MY, Abou-Ismail MY (2021). Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia. [Letter to the editor]. Thromb Res, 206, 9-13.
- Abou-Ismail MY, Moser KA, Smock KJ, Lim MY (2021). Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism. [Letter to the editor]. Am J Hematol, 96(9), E346-E349.